Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Investing

Posted By Uma Rajagopal

Posted on December 3, 2024

Sanofi announces its biggest China investment deal amid China-EU trade tensions

SHANGHAI (Reuters) -Sanofi plans to invest around 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, which will mark the French drugmaker’s largest single investment in China, the company said on Monday.

The site, which will be in the Beijing Economic and Technological Development Zone, will be Sanofi’s fourth production and supply base in China, Sanofi said in its official WeChat account.

China is seeking to strengthen economic ties with individual members of the European Union, even as its trade relations with the 27-nation bloc soured over issues including accusations of Chinese government subsidies to the electric vehicle industry.

In a Monday meeting with Sanofi Chairman Frederic Oudea in Beijing, Chinese Commerce Minister Wang Wentao said China will support all businesses equally in technological innovation and participating in market competition, a ministry statement said.

China will continue to open up its market, and is committed to building a business environment for companies including Sanofi to operate and develop with “peace of mind,” Wang added.

($1 = 0.9500 euro)

(Reporting by Brenda Goh, additional reporting by Beijing Newsroom; Editing by Louise Heavens and Jonathan Oatis)

Recommended for you

  • UK’s FTSE 100 logs biggest weekly gain in 5 weeks

  • UK’s FTSE 100 little changed after holiday break; indexes set for weekly gains

  • European shares crawl higher to one-week high on tech boost